20% off purchase of 3 or more products* | Learn More >>

Polyclonal Antibody Monocyte Chemotaxis

Also showing Polyclonal Antibody Western Blotting Monocyte Chemotaxis

$260
100 µl
APPLICATIONS
REACTIVITY
Human

Application Methods: Western Blotting

Background: Monocyte chemotactic protein-1 (MCP-1), also known as CCL2, monocyte chemotactic activating factor (MCAF) or glioma-derived chemotactic factor-2 (GDCF-2), is the product of the human JE gene and a member of the family of C-C (or β) chemokines (1-4). The predicted molecular weight of MCP-1 protein is 11-13 kDa, but it may migrate at 20-30 kDa due to glycosylation. MCP-1 is secreted by a variety of cell types in response to pro-inflammatory stimuli and was originally described for its chemotactic activity on monocytes. This activity has led to studies demonstrating its role in diseases characterized by monocyte infiltrates such as psoriasis (5), rheumatoid arthritis (6) and atherosclerosis (7). MCP-1 may also contribute to tumor progression and angiogenesis (8). Signaling by MCP-1 is mediated by the G-protein coupled receptor CCR2 (9).

$260
100 µl
APPLICATIONS
REACTIVITY
Human

Application Methods: Immunoprecipitation, Western Blotting

Background: Monocyte chemotactic protein-1 (MCP-1), also known as CCL2, monocyte chemotactic activating factor (MCAF) or glioma-derived chemotactic factor-2 (GDCF-2), is the product of the human JE gene and a member of the family of C-C (or β) chemokines (1-4). The predicted molecular weight of MCP-1 protein is 11-13 kDa, but it may migrate at 20-30 kDa due to glycosylation. MCP-1 is secreted by a variety of cell types in response to pro-inflammatory stimuli and was originally described for its chemotactic activity on monocytes. This activity has led to studies demonstrating its role in diseases characterized by monocyte infiltrates such as psoriasis (5), rheumatoid arthritis (6) and atherosclerosis (7). MCP-1 may also contribute to tumor progression and angiogenesis (8). Signaling by MCP-1 is mediated by the G-protein coupled receptor CCR2 (9).

$260
100 µl
APPLICATIONS
REACTIVITY
Human

Application Methods: Western Blotting

Background: RANTES/CCL5 (regulated upon activation, T cell expressed and secreted) is a member of the "C-C" or β family of chemokines that induce inflammation and are associated with a number of inflammatory disorders (1,2). RANTES is produced and secreted mainly by CD8+ T cells, macrophages, and platelets, as well as epithelial cells, fibroblasts and some solid tumors (2-7). RANTES acts as a chemoattractant and has other regulatory functions on a number of cell types including monocytes, memory T cells, NK cells, eosinophils, basophils, dendritic cells, and mast cells (3, 7-9). Signaling by RANTES is mediated by several G-protein coupled receptors (GPCRs), including CCR1, CCR3, CCR4 and CCR5.

$260
100 µl
APPLICATIONS
REACTIVITY
Human

Application Methods: Western Blotting

Background: RANTES/CCL5 (regulated upon activation, T cell expressed and secreted) is a member of the "C-C" or β family of chemokines that induce inflammation and are associated with a number of inflammatory disorders (1,2). RANTES is produced and secreted mainly by CD8+ T cells, macrophages, and platelets, as well as epithelial cells, fibroblasts and some solid tumors (2-7). RANTES acts as a chemoattractant and has other regulatory functions on a number of cell types including monocytes, memory T cells, NK cells, eosinophils, basophils, dendritic cells, and mast cells (3, 7-9). Signaling by RANTES is mediated by several G-protein coupled receptors (GPCRs), including CCR1, CCR3, CCR4 and CCR5.

$260
100 µl
APPLICATIONS
REACTIVITY
Mouse

Application Methods: Immunoprecipitation, Western Blotting

Background: RANTES/CCL5 (regulated upon activation, T cell expressed and secreted) is a member of the "C-C" or β family of chemokines that induce inflammation and are associated with a number of inflammatory disorders (1,2). RANTES is produced and secreted mainly by CD8+ T cells, macrophages, and platelets, as well as epithelial cells, fibroblasts and some solid tumors (2-7). RANTES acts as a chemoattractant and has other regulatory functions on a number of cell types including monocytes, memory T cells, NK cells, eosinophils, basophils, dendritic cells, and mast cells (3, 7-9). Signaling by RANTES is mediated by several G-protein coupled receptors (GPCRs), including CCR1, CCR3, CCR4 and CCR5.

$260
100 µl
APPLICATIONS
REACTIVITY
Human, Mouse, Rat

Application Methods: Western Blotting

Background: Galectins are a family of β-galactose binding proteins that are characterized by an affinity for poly-N-acetyllactosamine-enriched glycoconjugates and a carbohydrate-binding site (1,2). Members of the galectin family have been implicated in a variety of biological functions including cell adhesion (3), growth regulation (4), cytokine production (5), T-cell apoptosis (6), and immune responses (7).Galectin-3/LGALS3 is involved in several diverse biological functions. Galectin-3/LGALS3 binds IgE (8). Galectin-3/LGALS3 is an unusual protein in that can be found both extracellularly and intracellularly. Intracellularly, galectin-3/LGALS3 can localize to the cytoplasm, nucleus, or both, depending on cell type and experimental conditions. Nuclear galectin-3/LGALS3 has been identified as a pre-mRNA splicing factor (9). Galectin-3/LGALS3 production has been shown to increase during inflammation and in obesity, and the protein itself can have an inflammatory effect under certain conditions (10). Galectin-3/LGALS3 forms a complex with α3, β1 integrin to act as a surface receptor on endothelial cells for the NG2 proteoglycan, which triggers cell motility and angiogenesis (11). In addition to these functions, galectin-3/LGALS3 is also a required factor for the terminal differentiation of epithelial cells (12).

$260
100 µl
APPLICATIONS
REACTIVITY
Human

Application Methods: Immunoprecipitation, Western Blotting

Background: RANK (receptor activator of NF-κB) is a member of the tumor necrosis factor (TNF) receptor subfamily that is activated by its ligand, RANKL (TRANCE/OPGL/ODF), to promote survival of dendritic cells and differentiation of osteoclasts (1-4). Although RANK is widely expressed, its cell surface expression may be more restricted to dendritic cells and foreskin fibroblasts (1). RANK contains a 383-amino acid intracellular domain that associates with specific members of the TRAF family to NF-κB and JNK activiation (1,5). RANKL/RANK signaling may also lead to survival signaling through activation of the Akt pathway and an upregulation of survival proteins, including Bcl-xL (2,6). RANK signaling has been implicated as a potential therapeutic to inhibit bone loss and arthritis (7,8).

$260
100 µl
APPLICATIONS
REACTIVITY
Human

Application Methods: Immunoprecipitation, Western Blotting

Background: RANK (receptor activator of NF-κB) is a member of the tumor necrosis factor (TNF) receptor subfamily that is activated by its ligand, RANKL (TRANCE/OPGL/ODF), to promote survival of dendritic cells and differentiation of osteoclasts (1-4). Although RANK is widely expressed, its cell surface expression may be more restricted to dendritic cells and foreskin fibroblasts (1). RANK contains a 383-amino acid intracellular domain that associates with specific members of the TRAF family to NF-κB and JNK activiation (1,5). RANKL/RANK signaling may also lead to survival signaling through activation of the Akt pathway and an upregulation of survival proteins, including Bcl-xL (2,6). RANK signaling has been implicated as a potential therapeutic to inhibit bone loss and arthritis (7,8).

$260
100 µl
APPLICATIONS
REACTIVITY
Human, Mouse, Rat

Application Methods: Western Blotting

Background: RANK (receptor activator of NF-κB) is a member of the tumor necrosis factor (TNF) receptor subfamily that is activated by its ligand, RANKL (TRANCE/OPGL/ODF), to promote survival of dendritic cells and differentiation of osteoclasts (1-4). Although RANK is widely expressed, its cell surface expression may be more restricted to dendritic cells and foreskin fibroblasts (1). RANK contains a 383-amino acid intracellular domain that associates with specific members of the TRAF family to NF-κB and JNK activiation (1,5). RANKL/RANK signaling may also lead to survival signaling through activation of the Akt pathway and an upregulation of survival proteins, including Bcl-xL (2,6). RANK signaling has been implicated as a potential therapeutic to inhibit bone loss and arthritis (7,8).

$260
100 µl
APPLICATIONS
REACTIVITY
Human

Application Methods: Western Blotting

Background: The vascular endothelial growth factor (VEGF) receptor (VEGFR-1, Flt-1) is a 180 kDa receptor tyrosine kinase belonging to the VEGFR (Flt) family (1-3). The receptor is comprised of seven extracellular Ig-like domains, a single transmembrane region and cytoplasmic tail containing the active kinase domain (1,2). VEGFR-1 plays an important role in endothelial cell function and normal vascular development, as well as in hematopoietic function (2,3). VEGF-A is a high affinity ligand of VEGFR-1. VEGFR-1 also binds VEGF-B and PLGF (2). Ligand binding results in very little VEGFR-1 kinase activation, and VEGFR-1/VEGF-A binding negatively regulates VEGF function by diverting the growth factor from other functional VEGF receptors (3).